Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EDSA Stock Forecast 2026-2027
$5.93
Current Price
$52.69M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EDSA Price Targets
+220.4%
To High Target of $19.00
+51.8%
To Median Target of $9.00
-15.7%
To Low Target of $5.00
EDSA Price Momentum
+7.4%
1 Week Change
-18.0%
1 Month Change
+162.4%
1 Year Change
+317.6%
Year-to-Date Change
-36.7%
From 52W High of $9.37
+723.6%
From 52W Low of $0.72
📊 TOP ANALYST CALLS
Did EDSA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Edesa Biotech is one of their latest high-conviction picks.
Latest EDSA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, EDSA has a bullish consensus with a median price target of $9.00 (ranging from $5.00 to $19.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $5.93, the median forecast implies a 51.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 15.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EDSA Analyst Ratings
2
Buy
0
Hold
0
Sell
EDSA Price Target Range
Low
$5.00
Average
$9.00
High
$19.00
Current: $5.93
Latest EDSA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EDSA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $5.00 |
| Jun 27, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Assumes | $5.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $21.00 |
| Nov 29, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $21.00 |
| Nov 22, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $10.00 |
| Oct 12, 2023 | Brookline Capital | Kemp Dolliver | Buy | Maintains | $57.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $10.00 |
| May 24, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $16.00 |
| Mar 15, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $16.00 |
| Feb 14, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $16.00 |
| Dec 20, 2021 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $16.00 |
Edesa Biotech Inc. (EDSA) Competitors
The following stocks are similar to Edesa Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Edesa Biotech Inc. (EDSA) Financial Data
Edesa Biotech Inc. has a market capitalization of $52.69M with a P/E ratio of -4.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -96.4%.
Valuation Metrics
Market Cap
$52.69M
Enterprise Value
$46.75M
P/E Ratio
-4.7x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+24.4%
Current Ratio
16.8x
Debt/Equity
0.0x
ROE
-96.4%
ROA
-55.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Edesa Biotech Inc. (EDSA) Business Model
About Edesa Biotech Inc.
What They Do
Develops innovative therapies for dermatological conditions.
Business Model
Edesa Biotech Inc. operates as a clinical-stage pharmaceutical company, focusing on the development and commercialization of small molecule drugs and biologics for dermatological and gastrointestinal indications. The company generates revenue through the successful advancement of its drug candidates, particularly by addressing unmet medical needs in skin health and securing regulatory approvals for its therapies.
Additional Information
Edesa Biotech's pipeline includes treatments for conditions like atopic dermatitis and allergic contact dermatitis. By leveraging proprietary research and extensive clinical expertise, the company aims to deliver novel treatment options and contribute to medical advancements in the competitive biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Dr. Pardeep Nijhawan FRCPC, M.D.
Country
Canada
IPO Year
2019
Website
www.edesabiotech.comEdesa Biotech Inc. (EDSA) Latest News & Analysis
Latest News
Quick Summary
Paridiprubart shows statistically significant mortality reductions in ARDS patients, following positive Phase 3 trial results, indicating potential market viability.
Why It Matters
Positive Phase 3 results for Paridiprubart indicate potential market success and revenue growth, impacting stock prices and investor sentiment in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Edesa Biotech (Nasdaq: EDSA) updated on its Phase 2 study of EB06 for moderate-to-severe nonsegmental vitiligo, reaffirming enrollment timelines amid its participation in the GVF Symposium.
Why It Matters
Edesa Biotech's update on its Phase 2 study for EB06 and participation in a key symposium may boost investor confidence in its pipeline's potential and market positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Edesa Biotech (Nasdaq: EDSA) reported positive additional data from a Phase 3 study of its drug paridiprubart, aimed at immuno-inflammatory diseases.
Why It Matters
Positive Phase 3 data for paridiprubart enhances Edesa Biotech's growth potential, likely boosting stock value and attracting investor interest in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Edesa Biotech, Inc. (Nasdaq:EDSA) reported its Q4 2025 financial results and provided a business update focused on developing therapeutics for immuno-inflammatory diseases.
Why It Matters
Edesa Biotech's quarterly financial results and business update indicate its operational health and future growth potential, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Edesa Biotech Reports Fiscal Year 2025 Results
4 months ago
Quick Summary
Edesa Biotech, Inc. (Nasdaq:EDSA) reported its fiscal year 2025 financial results and provided a business update, focusing on host-directed therapeutics for immuno-inflammatory diseases.
Why It Matters
Edesa Biotech's financial results and business update can influence stock performance, reflecting its growth potential and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Edesa Biotech Announces Upcoming Conference Schedule
5 months ago
Quick Summary
Edesa Biotech, Inc. (Nasdaq:EDSA) will participate in upcoming conferences, focusing on developing therapeutics for immuno-inflammatory diseases.
Why It Matters
Edesa Biotech's participation in key conferences could signal potential partnerships or funding opportunities, impacting its stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EDSA Stock
What is Edesa Biotech Inc.'s (EDSA) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Edesa Biotech Inc. (EDSA) has a median price target of $9.00. The highest price target is $19.00 and the lowest is $5.00.
Is EDSA stock a good investment in 2026?
According to current analyst ratings, EDSA has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EDSA stock?
Wall Street analysts predict EDSA stock could reach $9.00 in the next 12 months. This represents a 51.8% increase from the current price of $5.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Edesa Biotech Inc.'s business model?
Edesa Biotech Inc. operates as a clinical-stage pharmaceutical company, focusing on the development and commercialization of small molecule drugs and biologics for dermatological and gastrointestinal indications. The company generates revenue through the successful advancement of its drug candidates, particularly by addressing unmet medical needs in skin health and securing regulatory approvals for its therapies.
What is the highest forecasted price for EDSA Edesa Biotech Inc.?
The highest price target for EDSA is $19.00 from at , which represents a 220.4% increase from the current price of $5.93.
What is the lowest forecasted price for EDSA Edesa Biotech Inc.?
The lowest price target for EDSA is $5.00 from Yi Chen at HC Wainwright & Co., which represents a -15.7% decrease from the current price of $5.93.
What is the overall EDSA consensus from analysts for Edesa Biotech Inc.?
The overall analyst consensus for EDSA is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are EDSA stock price projections?
Stock price projections, including those for Edesa Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 3:58 PM UTC